https://www.mynewsdesk.com/se/scandinavian-biopharma Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. https://www.mynewsdesk.com/se/scandinavian-biopharma https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 sv 15 Fri, 20 Feb 2026 14:57:12 +0100 Scandinavian Biopharma meddelar att de fullständiga resultaten från bolagets fas 2b-studie av ETVAX®, bolagets ledande orala vaccinkandidat mot enterotoxinbildande Escherichia coli (ETEC), har publicerats i The Lancet Infectious Diseases – en av världens mest ansedda medicinska tidskrifter. EMA bekräftar att ETVAX® är redo för fas 3. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharmas-fas-2b-resultat-publiceras-i-the-lancet-infectious-diseases-etvax-r-redo-foer-fas-3-3433770?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharmas-fas-2b-resultat-publiceras-i-the-lancet-infectious-diseases-etvax-r-redo-foer-fas-3-3433770?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Fri, 20 Feb 2026 14:49:16 +0100 Scandinavian Biopharma today announces that the comprehensive results from its Phase 2b trial of ETVAX®, the lead oral vaccine candidate against enterotoxigenic Escherichia coli (ETEC), have been published in The Lancet Infectious Diseases. ETVAX® is considered Phase 3 ready for the prevention of moderate-to-severe ETEC diarrhoea in infants and young children in low- and middle-income countries. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-announces-publication-of-etvax-r-phase-2b-data-in-the-lancet-infectious-diseases-and-confirms-phase-3-readiness-3433766?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-announces-publication-of-etvax-r-phase-2b-data-in-the-lancet-infectious-diseases-and-confirms-phase-3-readiness-3433766?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Wed, 02 Oct 2024 09:09:16 +0200 Scandinavian Biopharma is pleased to announce the successful completion of its large pediatric Phase IIb trial for ETVAX®, a promising vaccine candidate against enterotoxigenic Escherichia coli (ETEC), commonly called traveler’s diarrhea, conducted in The Gambia. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-announces-successful-completion-of-pediatric-phase-iib-trial-for-etvax-r-vaccine-in-the-gambia-3346338?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-announces-successful-completion-of-pediatric-phase-iib-trial-for-etvax-r-vaccine-in-the-gambia-3346338?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Wed, 02 Oct 2024 09:03:51 +0200 Scandinavian Biopharma rapporterar positiva resultat från företagets stora pediatriska fas IIb-studie, genomförd i Gambia, med ETVAX®. ETVAX® är en lovande vaccinkandidat mot enterotoxinogena Escherichia coli (ETEC), även kallad turistdiarré. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-rapporterar-lovande-resultat-fraan-pediatrisk-fas-iib-studie-i-gambia-med-sitt-etvax-r-vaccin-3346324?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-rapporterar-lovande-resultat-fraan-pediatrisk-fas-iib-studie-i-gambia-med-sitt-etvax-r-vaccin-3346324?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Wed, 07 Aug 2024 09:35:04 +0200 Scandinavian Biopharma and The European Commission’s Health Emergency Preparedness and Response Authority (HERA) has signed a joint procurement framework contract for the supply of diphtheria antitoxin. This joint procurement will facilitate access to diphtheria antitoxin for the Member States and will ensure that those who need treatment are able to access it in a timely manner. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-signs-a-joint-procurement-with-eu-commission-to-supply-diphtheria-antitoxin-3336456?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-signs-a-joint-procurement-with-eu-commission-to-supply-diphtheria-antitoxin-3336456?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Mon, 29 Apr 2024 13:32:55 +0200 Scandinavian Biopharma is pleased to announce another year of significant growth. For the full year 2023, the revenue increased by over 33 MSEK, corresponding an organic growth of 27%. The total revenue for 2023 amounted to 154 MSEK. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-reports-27-procent-growth-for-2023-and-initiates-a-pre-study-ahead-of-phase-iii-3319912?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-reports-27-procent-growth-for-2023-and-initiates-a-pre-study-ahead-of-phase-iii-3319912?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Mon, 29 Apr 2024 13:28:28 +0200 Scandinavian Biopharma har glädjen att meddela ännu ett år med betydande tillväxt. För helåret 2023 redovisades en ökning av omsättningen med över 33 MSEK, vilket motsvarar en organisk tillväxt på 27%. Den totala omsättningen för 2023 uppgick till 154 MSEK. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-rapporterar-27-procent-tillvaext-foer-2023-och-start-av-foerstudie-infoer-fas-iii-3319905?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-rapporterar-27-procent-tillvaext-foer-2023-och-start-av-foerstudie-infoer-fas-iii-3319905?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Wed, 27 Sep 2023 09:44:01 +0200 Scandinavian Biopharma Distribution AB has extended and expanded its distribution agreement with Neovii Pharmaceuticals AG. This collaboration involves an extension of the agreement for the immunosuppressive drug Grafalon (anti-human T-lymphocyte immunoglobulin, ATLG) in Sweden, Norway, and Denmark, and now also includes Finland, thus encompassing all the Nordic countries. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-and-neovii-extend-and-expand-their-distribution-agreement-for-the-transplantation-product-grafalon-3275895?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-and-neovii-extend-and-expand-their-distribution-agreement-for-the-transplantation-product-grafalon-3275895?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Wed, 27 Sep 2023 09:39:16 +0200 Scandinavian Biopharma Distribution AB har förlängt och utökat sitt distributionsavtal med Neovii Pharmaceuticals AG. Detta samarbete innebär en förlängning av avtalet för det immunosuppressiva läkemedlet Grafalon (anti-human T-lymfocytimmunglobulin, ATLG) i Sverige, Norge och Danmark och inkluderar nu även Finland, därmed inkluderar avtalet samtliga nordiska länder. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-och-neovii-utoekar-och-foerdjupar-sitt-samarbete-med-transplantationsprodukten-grafalon-3275881?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-och-neovii-utoekar-och-foerdjupar-sitt-samarbete-med-transplantationsprodukten-grafalon-3275881?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Mon, 18 Sep 2023 11:00:21 +0200 Reckitt har utsett Scandinavian Biopharma som distributör för deras Nutramigen-sortimentet i Norden. Produkterna klassas som livsmedel för speciella medicinska ändamål, Food for Special Medical Purposes (FSMP), och används av spädbarn och småbarn med komjölksproteinallergi. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/reckitt-vaeljer-scandinavian-biopharma-som-distributoer-foer-nutramigen-sortimentet-i-norden-3273613?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/reckitt-vaeljer-scandinavian-biopharma-som-distributoer-foer-nutramigen-sortimentet-i-norden-3273613?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Thu, 01 Jun 2023 10:17:56 +0200 Scandinavian Biopharma är stolta över att välkomna Christine Hägglund till bolaget som VP CMC Development. Christine kommer att ta ansvar för att leda och utveckla bolagets CMC och analysverksamhet. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/christine-haegglund-blir-ny-vp-cmc-development-hos-scandinavian-biopharma-3256600?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/christine-haegglund-blir-ny-vp-cmc-development-hos-scandinavian-biopharma-3256600?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Mon, 03 Apr 2023 09:09:02 +0200 It is with great pleasure that we present another really good year of growth. The figures for the full year 2022 add up to an increase in sales equivalent to 30% in organic growth. In total, sales amount to approximately SEK 122 million. Our ETEC vaccine candidate, ETVAX, is about to enter phase 3. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-presents-the-year-end-report-for-2022-with-a-30-procent-growth-record-sales-and-the-etec-vaccine-candidate-about-to-enter-phase-3-3243804?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-presents-the-year-end-report-for-2022-with-a-30-procent-growth-record-sales-and-the-etec-vaccine-candidate-about-to-enter-phase-3-3243804?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Mon, 03 Apr 2023 09:09:02 +0200 Det är med stor glädje vi presenterar ännu ett riktigt bra år. För helåret 2022 summerar vi en ökning av omsättningen med drygt 28 MSEK motsvarande 30% i organisk tillväxt. Totalt uppgick omsättningen för 2022 till 122 MSEK. Vår ETEC-vaccinkandidat, ETVAX, är på väg in i fas 3. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-rapporterar-bokslutskommunike-foer-2022-med-30-procent-tillvaext-rekordomsaettning-foer-distributionsverksamheten-och-etec-vaccinkandiaten-paa-vaeg-in-i-fas-3-3243835?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-rapporterar-bokslutskommunike-foer-2022-med-30-procent-tillvaext-rekordomsaettning-foer-distributionsverksamheten-och-etec-vaccinkandiaten-paa-vaeg-in-i-fas-3-3243835?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Mon, 19 Dec 2022 13:26:44 +0100 Via våra kontakter i Benin har vi precis levererat över 300 impregnerade myggnät till tre olika barnhem. Samtliga barn och ungdomar, som är mellan 4 och 18 år, i detta malariautsatta område kommer nu kunna sova tryggt under dessa högkvalitativa myggnät. Myggnäteten ger ett enkelt men livsavgörande skydd för dessa barn. En gåva som räddar liv! https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-skaenker-myggnaet-till-barnhem-i-benin-gaavor-som-raeddar-liv-3224491?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-skaenker-myggnaet-till-barnhem-i-benin-gaavor-som-raeddar-liv-3224491?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Mon, 19 Dec 2022 13:21:45 +0100 We have just delivered over 300 impregnated mosquito nets to three different orphanages via our contacts in Benin. In this malaria-prone area, all the children and young people between 4 and 18 years, will now be able to sleep safely under these high-quality mosquito nets. The mosquito nets provide a simple but vital protection for these children. A gift that saves lives! https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-donates-mosquito-nets-to-orphanages-in-benin-a-gift-that-saves-lives-3224445?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-donates-mosquito-nets-to-orphanages-in-benin-a-gift-that-saves-lives-3224445?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Mon, 05 Dec 2022 11:31:17 +0100 At the annual PATH-hosed Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference, diarrhea is always the center of the conversation, and this year's gathering was no exception. During the 2022 VASE Conference in Washington, DC last week more than 300 experts traveled from around the world to learn about the latest enteric vaccine research. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/new-etvax-r-data-was-presented-during-vase-an-international-gathering-dedicated-to-develop-shigella-and-etec-vaccines-3221713?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/new-etvax-r-data-was-presented-during-vase-an-international-gathering-dedicated-to-develop-shigella-and-etec-vaccines-3221713?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Thu, 24 Nov 2022 10:19:28 +0100 Scandinavian Biopharma fortsätter att stärka sin organisation inom tillverkning och är glada att välkomna Johan Jarmander som nya Drug Substance Specialist Manufacturing & Development. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-vaelkomnar-johan-jarmander-till-tjaensten-som-drug-substance-specialist-manufacturing-och-development-3219620?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-vaelkomnar-johan-jarmander-till-tjaensten-som-drug-substance-specialist-manufacturing-och-development-3219620?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Thu, 24 Nov 2022 10:15:49 +0100 Scandinavian Biopharma continues to strengthen its organization in manufacturing and is pleased to welcome Johan Jarmander as our new Drug Substance Specialist Manufacturing & Development. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-welcomes-johan-jarmander-to-the-position-as-drug-substance-specialist-manufacturing-och-development-3219615?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-welcomes-johan-jarmander-to-the-position-as-drug-substance-specialist-manufacturing-och-development-3219615?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Wed, 16 Nov 2022 08:36:50 +0100 Scandinavian Biopharma och Novavax har tecknat ett kommersiellt samarbetsavtal för Covidvaccinet Nuvaxovid. Från och med oktober 2022 är företaget representant för Nuvaxovid på den svenska marknaden och kommer att hjälpa Novavax med försäljning och marknadsföring av vaccinet. Nuvaxovid är ett adjuvanterat proteinbaserat vaccin som skyddar mot SARS Covid-19. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-ingaar-ett-kommersiellt-samarbete-med-novavax-i-sverige-3217805?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-ingaar-ett-kommersiellt-samarbete-med-novavax-i-sverige-3217805?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma Wed, 16 Nov 2022 08:30:53 +0100 Scandinavian Biopharma and Novavax have signed a commercial collaboration agreement for the Covid vaccine Nuvaxovid. As of October 2022, the company is the representative for Nuvaxovid on the Swedish market and will assist Novavax with the sales and marketing of the vaccine. Nuvaxovid is an adjuvanted protein-based vaccine that protects against SARS Covid-19. https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-enters-into-a-commercial-collaboration-with-novavax-in-sweden-3217798?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/scandinavian-biopharma/pressreleases/scandinavian-biopharma-enters-into-a-commercial-collaboration-with-novavax-in-sweden-3217798?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Scandinavian Biopharma